Ibrance
/
Ibrance (palbociclib) is a kinase inhibitor used in combination with other medications to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in adults. It is administered as an oral tablet and is available by prescription only. Patients are advised to monitor for signs of infection, as Ibrance may cause low white blood cell counts, increasing the risk of serious infections.
Pay securely with Zelle
FAQs about Ibrance
What should I do if I miss a dose?
If you miss a dose of Ibrance (palbociclib), take it as soon as you remember on the same day. However, if it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed dose. This information is provided in the Patient Counseling Information section of the label.
Can I take Ibrance while pregnant or breastfeeding?
Ibrance is not recommended for use during pregnancy due to potential harm to the fetus. Women who are pregnant or planning to become pregnant should discuss the risks with their healthcare provider. It is advised that women do not breastfeed while taking Ibrance, as it may pass into breast milk. This information is found in the Warnings and Precautions section of the label.
Can I stop taking Ibrance suddenly?
Patients are advised not to stop taking Ibrance abruptly without consulting their healthcare provider. Discontinuation should be discussed with a healthcare professional to ensure proper management of the treatment plan. This guidance is included in the Dosage and Administration section of the label.
How should I store Ibrance?
Ibrance should be stored at room temperature, between 20°C to 25°C (68°F to 77°F). It should be kept in its original container and protected from moisture and light. This storage information is detailed in the Storage and Handling section of the label.
25
commonly-prescribed
medication.
🍪 We use cookies
We use cookies to enhance your browsing experience, serve personalised content, and analyse traffic. By clicking "Accept all", you consent to our use of cookies.